The relationship between homocysteine and autoimmune subclinical hypothyroidism

TURHAN, Turan; Ates, Ihsan; bolal, mehmet; yılmaz, nisbet; ALTAY, Mustafa; Demir, Burak

doi:10.14744/ijmb.2019.13008

The relationship between homocysteine and autoimmune subclinical hypothyroidism

Mehmet BOLAL, (Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Ihsan ATEŞ, (Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Burak Furkan DEMİR, (Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Mustafa ALTAY, (Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi, Endokrinoloji Kliniği, Ankara, Türkiye)

Turan TURHAN, (Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi, Biyokimya Bölümü, Ankara, Türkiye)

Nisbet YILMAZ (Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

International Journal of Medical Biochemistry

14 0

Yıl: 2020 Cilt: 3 Sayı: 1 Sayfa Aralığı: 1 - 7 Metin Dili: İngilizce DOI: 10.14744/ijmb.2019.13008 İndeks Tarihi: 24-09-2020

The relationship between homocysteine and autoimmune subclinical hypothyroidism

Öz:

Objectives: Homocysteine, an atherosclerotic marker, is thought to be associated with chronic inflammation and autoimmunity.The aim of this study was to investigate the association between the homocysteine level, lipid parameters,high-sensitivity C-reactive protein (hs-CRP), and autoantibodies in subclinical hypothyroid patients.Methods: A total of 100 cases, 50 patients who were older than 18 years of age and diagnosed with subclinical hypothyroidismdue to Hashimoto’s thyroiditis and 50 controls with no known disease, were included in the study.Results: Homocysteine (9.6 μmol/L vs 5.5 μmol/L; p<0.001), hs-CRP (2.4 mg/L vs 0.9 mg/L; p<0.001), and low-densitylipoprotein-cholesterol levels (115.9±32.7 mg/dL vs 100.3±23.9 mg/dL) (p=0.008) were determined to be higher in thesubclinical hypothyroidism group, and the high-density lipoprotein (HDL) cholesterol level (51.2±12.7 mg/dL vs 58.8±15.2mg/dL; p=0.008) was lower in the subclinical hypothyroidism group compared with the healthy control group. A positivecorrelation was determined between the homocysteine level and the hs-CRP (r=0.312; p=0.027), anti-thyroid peroxidase(r=0.505; p<0.001), and anti-thyroglobulin (r=0.318; p=0.031) levels in the subclinical hypothyroidism group.Conclusion: In the regression analysis performed, HDL cholesterol, hs-CRP, and homocysteine levels were each foundto be an independent risk factor for subclinical hypothyroidism. Our results indicated that homocysteine was associatedwith subclinical hypothyroidism.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Mikoś H, Mikoś M, Obara-Moszyńska M, Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol 2014;65(2):150–5.
2. Altay M, Ateş İ, Yılmaz FM, Topçuoğlu C, Kaplan M. The role of circulating sTWEAK in the pathogenesis of Hashimoto's thyroiditis - a pilot study. Endokrynol Pol 2016;67(6):562–66.
3. Altay M, Karakoç MA, Çakır N, Yılmaz Demirtaş C, Cerit ET, Aktürk M, et al. Serum Total Sialic Acid Level is Elevated in Hypothyroid Patients as an Atherosclerotic Risk Factor. J Clin Lab Anal 2017;31(2).
4. Sato Y, Yoshihisa A, Kimishima Y, Kiko T, Watanabe S, Kanno Y, et al. Subclinical Hypothyroidism Is Associated With Adverse Prognosis in Heart Failure Patients. Can J Cardiol 2018;34:80–7.
5. Kim H, Kim TH, Kim HI, Park SY, Kim YN, Kim S, et al. Subclinical thyroid dysfunction and risk of carotid atherosclerosis. PLoS One 2017;12(7):e0182090.
6. Aziz M, Kandimalla Y, Machavarapu A, Saxena A, Das S, Younus A, et al. Effect of Thyroxin Treatment on Carotid Intima-Media Thickness (CIMT) Reduction in Patients with Subclinical Hypothyroidism (SCH): a Meta-Analysis of Clinical Trials. J Atheroscler Thromb 2017;24(7):643–59.
7. Delitala AP, Fanciulli G, Maioli M, Delitala G. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. Eur J Intern Med.2017;38:17–24.
8. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27(3):517–27.
9. Seshadri N, Robinson K. Homocysteine, B vitamins, and coronary artery disease. Med Clin North Am 2000;84(1):215–37, x.
10. Karolczak K, Kubalczyk P, Glowacki R, Pietruszynski R, Watala C. Aldosterone modulates blood homocysteine and cholesterol in coronary artery disease patients-a possible impact on atherothrombosis? Physiol Res 2018;67(2):197–207.
11. Duan L, Hu J, Xiong X, Liu Y, Wang J. The role of DNA methylation in coronary artery disease. Gene 2018;646:91–7.
12. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 2014;13(4-5):391–7.
13. McCully KS.Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56(1):111–28.
14. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Circulation 1995;91(4):1161–74.
15. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells. Circulation 2001;103(22):2717–23.
16. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354(9176):407–13.
17. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Arterioscler Thromb Vasc Biol 1997;17(10):2074–81.
18. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281(22):2113–8.
19. Ueland PM, Mansoor MA, Guttormsen AB, Müller F, Aukrust P, Refsum H, et al. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status–a possible element of the extracellular antioxidant defense system. J Nutr 1996;126(4 Suppl):1281S–4S.
20. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91(1):308–18.
21. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004;140(2):94–100.
22. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RC, Alvarez JO, et al. Plasma homocyst (e) ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994;59(4):940–8.
23. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000;101(13):1506–11.
24. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine- lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002;288(8):973–9.
25. Tseng FY, Lin WY, Lin CC, Lee LT, Li TC, Sung PK, et al. Subclinical hypothyroidism is associated with increased risk for allcause and cardiovascular mortality in adults. J Am Coll Cardiol 2012;60(8):730–7.
26. Carbotta G, Tartaglia F, Giuliani A, Carbotta S, Tromba L, Jacomelli I, et al. Cardiovascular risk in chronic autoimmune thyroiditis and subclinical hypothyroidism patients. A cluster analysis. Int J Cardiol 2017;230:115–9.
27. İşgüven P, Gündüz Y, Kılıç M. Effects of thyroid autoimmunity on early atherosclerosis in euthyroid girls with Hashimoto’s thyroiditis. J Clin Res Pediatr Endocrinol 2016;8(2):150–6.
28. Vayá A, Giménez C, Sarnago A, Alba A, Rubio O, Hernández- Mijares A, et al. Subclinical hypothyroidism and cardiovascular risk. Clin Hemorheol Microcirc 2014;58(1):1–7.
29. França MM, Nogueira CR, Hueb JC, Mendes AL, Padovani CR, Mazeto GM. Higher carotid intima-media thickness in subclinical hypothyroidism associated with the metabolic syndrome. Metab Syndr Relat Disord 2016;14(8):381–5.
30. Deicher R, Vierhapper H. Homocysteine: a risk factor for cardiovascular disease in subclinical hypothyroidism? Thyroid 2002;12(8):733–6.
31. Turhan S, Sezer S, Erden G, Guctekin A, Ucar F, Ginis Z, et al. Plasma homocysteine concentrations and serum lipid profile as atherosclerotic risk factors in subclinical hypothyroidism. Ann Saudi Med 2008;28(2):96–101.
32. Sengül E, Cetinarslan B, Tarkun I, Cantürk Z, Türemen E. Homocysteine concentrations in subclinical hypothyroidism. Endocr Res 2004;30(3):351–9.
33. Owecki M, Dorszewska J, Sawicka-Gutaj N, Oczkowska A, Owecki MK, Michalak M,et al. Serum homocysteine levels are decreased in levothyroxine-treated women with autoimmune thyroiditis. BMC Endocr Disord 2014;14:18.

APA	bolal m, Ates I, Demir B, ALTAY M, TURHAN T, yılmaz n (2020). The relationship between homocysteine and autoimmune subclinical hypothyroidism. , 1 - 7. 10.14744/ijmb.2019.13008
Chicago	bolal mehmet,Ates Ihsan,Demir Burak,ALTAY Mustafa,TURHAN Turan,yılmaz nisbet The relationship between homocysteine and autoimmune subclinical hypothyroidism. (2020): 1 - 7. 10.14744/ijmb.2019.13008
MLA	bolal mehmet,Ates Ihsan,Demir Burak,ALTAY Mustafa,TURHAN Turan,yılmaz nisbet The relationship between homocysteine and autoimmune subclinical hypothyroidism. , 2020, ss.1 - 7. 10.14744/ijmb.2019.13008
AMA	bolal m,Ates I,Demir B,ALTAY M,TURHAN T,yılmaz n The relationship between homocysteine and autoimmune subclinical hypothyroidism. . 2020; 1 - 7. 10.14744/ijmb.2019.13008
Vancouver	bolal m,Ates I,Demir B,ALTAY M,TURHAN T,yılmaz n The relationship between homocysteine and autoimmune subclinical hypothyroidism. . 2020; 1 - 7. 10.14744/ijmb.2019.13008
IEEE	bolal m,Ates I,Demir B,ALTAY M,TURHAN T,yılmaz n "The relationship between homocysteine and autoimmune subclinical hypothyroidism." , ss.1 - 7, 2020. 10.14744/ijmb.2019.13008
ISNAD	bolal, mehmet vd. "The relationship between homocysteine and autoimmune subclinical hypothyroidism". (2020), 1-7. https://doi.org/10.14744/ijmb.2019.13008

APA	bolal m, Ates I, Demir B, ALTAY M, TURHAN T, yılmaz n (2020). The relationship between homocysteine and autoimmune subclinical hypothyroidism. International Journal of Medical Biochemistry, 3(1), 1 - 7. 10.14744/ijmb.2019.13008
Chicago	bolal mehmet,Ates Ihsan,Demir Burak,ALTAY Mustafa,TURHAN Turan,yılmaz nisbet The relationship between homocysteine and autoimmune subclinical hypothyroidism. International Journal of Medical Biochemistry 3, no.1 (2020): 1 - 7. 10.14744/ijmb.2019.13008
MLA	bolal mehmet,Ates Ihsan,Demir Burak,ALTAY Mustafa,TURHAN Turan,yılmaz nisbet The relationship between homocysteine and autoimmune subclinical hypothyroidism. International Journal of Medical Biochemistry, vol.3, no.1, 2020, ss.1 - 7. 10.14744/ijmb.2019.13008
AMA	bolal m,Ates I,Demir B,ALTAY M,TURHAN T,yılmaz n The relationship between homocysteine and autoimmune subclinical hypothyroidism. International Journal of Medical Biochemistry. 2020; 3(1): 1 - 7. 10.14744/ijmb.2019.13008
Vancouver	bolal m,Ates I,Demir B,ALTAY M,TURHAN T,yılmaz n The relationship between homocysteine and autoimmune subclinical hypothyroidism. International Journal of Medical Biochemistry. 2020; 3(1): 1 - 7. 10.14744/ijmb.2019.13008
IEEE	bolal m,Ates I,Demir B,ALTAY M,TURHAN T,yılmaz n "The relationship between homocysteine and autoimmune subclinical hypothyroidism." International Journal of Medical Biochemistry, 3, ss.1 - 7, 2020. 10.14744/ijmb.2019.13008
ISNAD	bolal, mehmet vd. "The relationship between homocysteine and autoimmune subclinical hypothyroidism". International Journal of Medical Biochemistry 3/1 (2020), 1-7. https://doi.org/10.14744/ijmb.2019.13008